PURPOSE: The aim of our study was to assess the diagnostic accuracy of acoustic structure quantification (ASQ) ultrasound software in estimating the degree of hepatic fibrosis compared to Fibroscan and liver biopsy. MATERIALS AND METHODS: Seventy-seven patients with chronic viral hepatitis B and C underwent standard ultrasound examination, ASQ, Fibroscan and liver biopsy. ASQ analysis was conducted by placing a single region of interest (ROI) on each image captured, and calculating mode, average and standard deviation. The sonographic technique was developed through a preliminary evaluation of 20 healthy volunteers. RESULTS: The area under the receiver operating characteristic (AUROC) curve for the diagnosis of cirrhosis (F≥4) with ASQ was 0.77, whereas for the diagnosis of any degree of fibrosis (F≥1) it was 0.71. The AUROC for the diagnosis of cirrhosis (F≥4) with Fibroscan was 0.98, while for the diagnosis of any degree of fibrosis (F≥1) it was 0.94. The difference between the AUROC was statistically significant (p<0.05). CONCLUSIONS: ASQ is a promising new ultrasound software programme which offers encouraging results in the diagnosis of both liver cirrhosis (F=4) and fibrosis (F≥1). However, to date it has not attained the same level of diagnostic performance as Fibroscan.
PURPOSE: The aim of our study was to assess the diagnostic accuracy of acoustic structure quantification (ASQ) ultrasound software in estimating the degree of hepatic fibrosis compared to Fibroscan and liver biopsy. MATERIALS AND METHODS: Seventy-seven patients with chronic viral hepatitis B and C underwent standard ultrasound examination, ASQ, Fibroscan and liver biopsy. ASQ analysis was conducted by placing a single region of interest (ROI) on each image captured, and calculating mode, average and standard deviation. The sonographic technique was developed through a preliminary evaluation of 20 healthy volunteers. RESULTS: The area under the receiver operating characteristic (AUROC) curve for the diagnosis of cirrhosis (F≥4) with ASQ was 0.77, whereas for the diagnosis of any degree of fibrosis (F≥1) it was 0.71. The AUROC for the diagnosis of cirrhosis (F≥4) with Fibroscan was 0.98, while for the diagnosis of any degree of fibrosis (F≥1) it was 0.94. The difference between the AUROC was statistically significant (p<0.05). CONCLUSIONS:ASQ is a promising new ultrasound software programme which offers encouraging results in the diagnosis of both liver cirrhosis (F=4) and fibrosis (F≥1). However, to date it has not attained the same level of diagnostic performance as Fibroscan.
Authors: F Piscaglia; V Salvatore; R Di Donato; M D'Onofrio; S Gualandi; A Gallotti; E Peri; A Borghi; F Conti; G Fattovich; E Sagrini; A Cucchetti; P Andreone; L Bolondi Journal: Ultraschall Med Date: 2011-02-14 Impact factor: 6.548
Authors: Yi Wang; Daniel R Ganger; Josh Levitsky; Laura A Sternick; Robert J McCarthy; Zongming E Chen; Charles W Fasanati; Bradley Bolster; Saurabh Shah; Sven Zuehlsdorff; Reed A Omary; Richard L Ehman; Frank H Miller Journal: AJR Am J Roentgenol Date: 2011-03 Impact factor: 3.959
Authors: Mireen Friedrich-Rust; Katrin Wunder; Susanne Kriener; Fariba Sotoudeh; Swantje Richter; Joerg Bojunga; Eva Herrmann; Thierry Poynard; Christoph F Dietrich; Johannes Vermehren; Stefan Zeuzem; Christoph Sarrazin Journal: Radiology Date: 2009-08 Impact factor: 11.105
Authors: Thomas Karlas; Joachim Berger; Nikita Garnov; Franziska Lindner; Harald Busse; Nicolas Linder; Alexander Schaudinn; Bettina Relke; Rima Chakaroun; Michael Tröltzsch; Johannes Wiegand; Volker Keim Journal: World J Gastroenterol Date: 2015-04-28 Impact factor: 5.742
Authors: Giulio Argalia; Giuseppe Tarantino; Claudio Ventura; Daniele Campioni; Corrado Tagliati; Paola Guardati; Alba Kostandini; Marco Marzioni; Gian Marco Giuseppetti; Andrea Giovagnoni Journal: Radiol Med Date: 2021-01-25 Impact factor: 3.469